Nick NorwitzMD PhD, Oxford-Harvard | Metabolic Health Educator | “Stay Curious”

Ozempic's secret: How GLP-1 medications tame food cravings before you eat

22 Apr 2025 · 1 min

Watch on YouTube

1:13

In this explanatory segment, the narrator illustrates how GLP‑1 receptor agonists—popular weight‑loss drugs such as Ozempic and Wegovy—enhance pre‑ingestive satiation by acting on hypothalamic circuits in both mice and humans. The researchers aimed to decode the neural mechanisms behind these drugs’ appetite‑suppressing effects. Their key finding is that, when participants receive a GLP‑1 agonist, they experience stronger satiation during the pre‑ingestion phase, especially when presented with food cues, effectively dampening the desire for highly craved foods. This pre‑emptive reduction in craving is presented as a central way these medications promote weight loss.

Chapters

Take a moment to imagine your culinary kryptonite, that food when it's placed out in front of you, you just can't resist, you need to have it. Imagine it was in front of you, imagine that feeling of desire you would have. Now, I want you to imagine what if you could snap your fingers and you had the power to just kill that desire entirely, modulate your brain activity at will so your culinary kryptonite was entirely diffused. GLP-1 increases pre-ingestive satiation via hypothalamic circuits in mice and humans. What the researchers behind this study wanted to do was decode some of the neural mechanisms by which GLP-1 receptor agonists, this new class of drugs that's all the rage for weight loss, like Ozempic and Wegovy, by which they affect the brain to promote satiation and thereby promote weight loss. And what they found was really interesting, that humans given GLP-1 receptor agonists had greater satiation in particular during the pre-ingestion phase. When provided with a food cue. So that's like me going by the Rosie's Bakery as a kid, and rather than needing that walnut dream, I'm like, "Eh, whatever." So humans provided with GLP-1 receptor agonists in general as a population have greater pre-ingestion satiation